Perindopril Erbumine and Indapamide Tablet
Description
PRINTOOT-PLUS
Perindopril Erbumine and Indapamide Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Perindopril Erbumine IP — 4 mg
Indapamide IP — 1.25 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
PRINTOOT-PLUS is a scientifically balanced antihypertensive combination of Perindopril Erbumine and Indapamide, formulated for the effective management of hypertension and long-term cardiovascular risk reduction. This combination provides dual blood pressure control by combining the renin-angiotensin system inhibition of Perindopril with the diuretic and vascular protective properties of Indapamide, resulting in superior blood pressure reduction and target organ protection.
Perindopril Erbumine is an angiotensin-converting enzyme (ACE) inhibitor that reduces angiotensin II formation, promotes vasodilation, decreases aldosterone secretion, and protects cardiovascular and renal function. Indapamide is a thiazide-like diuretic that reduces sodium and water retention while exerting direct vasodilatory effects, thereby enhancing antihypertensive efficacy.
PRINTOOT-PLUS is particularly beneficial in patients with essential hypertension, hypertension associated with diabetes, chronic kidney disease, left ventricular hypertrophy, elderly hypertension, and patients at increased cardiovascular risk requiring combination antihypertensive therapy.
Technical Knowledge of Perindopril Erbumine and Indapamide
Perindopril is converted to its active metabolite Perindoprilat, which inhibits ACE and reduces angiotensin II production. This leads to decreased peripheral vascular resistance, reduced aldosterone-mediated sodium retention, improved endothelial function, and cardiovascular protection.
Indapamide acts primarily in the distal convoluted tubule of the nephron, promoting sodium and water excretion. In addition to its diuretic action, it has direct vascular smooth muscle effects that contribute to sustained blood pressure reduction and arterial compliance improvement.
The combination of Perindopril and Indapamide provides complementary antihypertensive mechanisms with enhanced cardiovascular and renal protective benefits.
Mechanism of Action
Perindopril inhibits ACE, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, and protects cardiovascular and renal tissues.
Indapamide promotes sodium and water excretion, reduces plasma volume, decreases peripheral vascular resistance, improves arterial compliance, and enhances antihypertensive efficacy.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Dual antihypertensive mechanism
Provides cardiovascular and renal protection
Improves endothelial function
Reduces arterial stiffness
Supports blood pressure control in diabetic patients
Helps reduce left ventricular hypertrophy
Suitable for long-term hypertension management under medical supervision
Clinical Applications
PRINTOOT-PLUS is commonly prescribed for essential hypertension, uncontrolled hypertension requiring combination therapy, hypertension with diabetes mellitus, hypertension with chronic kidney disease, elderly hypertension, cardiovascular risk reduction, left ventricular hypertrophy, and long-term antihypertensive management.
Facts About Perindopril Erbumine and Indapamide
Perindopril is an evidence-based ACE inhibitor with proven cardiovascular and renal protective benefits, while Indapamide is a thiazide-like diuretic with strong antihypertensive efficacy and favorable metabolic effects. The combination has extensive clinical evidence supporting blood pressure reduction, stroke prevention, and reduction of cardiovascular events in hypertensive patients.
Key Facts
ACE inhibitor and thiazide-like diuretic combination
Perindopril Erbumine for cardiovascular and renal protection
Indapamide for sustained antihypertensive control
Effective in hypertension and diabetic cardiovascular patients
Supports long-term cardiovascular risk reduction
Evidence-based combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
PRINTOOT-PLUS is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, obesity, and cardiovascular disorders creates strong prescription demand and long-term market potential for this combination.
Why Choose PRINTOOT-PLUS for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Perindopril Erbumine and Indapamide Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
PRINTOOT-PLUS from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based antihypertensive therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Perindopril and Indapamide formulation.
